Phase 3
๐ Investigational Drug / Biologic
NCT06319820
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
๐ Arkansas Urology โ Little Rock, Arkansas
View Study & Screener โ